Q-omics provides the consensus-scored SMYD4 profile across patient tissues and cancer cell-line models. SMYD4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SMYD4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SMYD4 RNA expression shows 20,549 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SCLC, KIRC, and THYM as cancer lineages where SMYD4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMYD4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMYD4 survival associations across molecular data types. SMYD4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMYD4 RNA expression–survival associations across cancer types. High SMYD4 expression shows unfavorable associations in KICH, LGG and MESO, but favorable associations in SCLC, KIRC and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for SMYD4 RNA expression.
This table summarizes SMYD4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SMYD4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMYD4 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, KIRP, KICH and LIHC. The KIRC box plot shows higher SMYD4 RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with SMYD4 in patient tissues and cancer cell lines. In patient samples, SMYD4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMYD4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
